Literature DB >> 12848396

Health technology assessment: history and demand.

Andrew Stevens1, Ruairidh Milne, Amanda Burls.   

Abstract

Health technology assessment (HTA)--the provision to decision makers of information on the value of treatments and tests--has come of age in the last two decades. But it has deep roots in health care, with notable landmarks in (1) the mid eighteenth-century development of empiricism, (2) the twentieth century interest in outcomes and variation in health care, and (3) the pioneering work of Archie Cochrane and others in the 1970s. Three main forces have driven the recent developments of HTA: a combination of concerns about the adoption of unproven technologies, rising costs, and an inexorable rise in consumer expectations. The HTA response, essentially initiatives supporting the provision of reliable synthesised research information on the effects and costs of health technologies, have been well supported in the United Kingdom and internationally. We can be sure that HTA is here to stay.

Mesh:

Year:  2003        PMID: 12848396     DOI: 10.1093/pubmed/fdg022

Source DB:  PubMed          Journal:  J Public Health Med        ISSN: 0957-4832


  5 in total

Review 1.  The assessment of the quality of reporting of meta-analyses in diagnostic research: a systematic review.

Authors:  Brian H Willis; Muireann Quigley
Journal:  BMC Med Res Methodol       Date:  2011-12-09       Impact factor: 4.615

2.  Evidence-Based Decision Making 3: Health Technology Assessment.

Authors:  Daria O'Reilly; Richard Audas; Kaitryn Campbell; Meredith Vanstone; James M Bowen; Lisa Schwartz; Nazila Assasi; Ron Goeree
Journal:  Methods Mol Biol       Date:  2021

3.  Engaging the public in priority-setting for health technology assessment: findings from a citizens' jury.

Authors:  Devidas Menon; Tania Stafinski
Journal:  Health Expect       Date:  2008-09       Impact factor: 3.377

4.  Reimbursement decisions for medical services in Austria: an analysis of influencing factors for the hospital individual services catalogue between 2008 and 2020.

Authors:  Gregor Goetz; Dimitra Panteli; Reinhard Busse; Claudia Wild
Journal:  BMC Health Serv Res       Date:  2022-02-15       Impact factor: 2.655

5.  Application of the HTA Core Model for complex evaluation of the effectiveness and quality of Radium-223 treatment in patients with metastatic castration resistant prostate cancer.

Authors:  Beata Kiselova Bilekova; Beata Gavurova; Vladimír Rogalewicz
Journal:  Health Econ Rev       Date:  2018-10-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.